An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Condition: Alagille Syndrome
MeSH terms: Liver Diseases; Alagille Syndrome; Syndrome
Intervention: LUM001 (Maralixibat)
Intervention description: Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: Double (Participant, Investigator)
Enrollment: 34.0
Sex: All
Minimum age: 1 Year
Maximum age: 18 Years
Healthy volunteers: No

Summary:

      This is a multicentre, extension study of LUM001 in children diagnosed with Alagille Syndrome
      who have completed participation in a core LUM001 treatment protocol. The primary objective
      is to evaluate long-term safety and tolerability of LUM001. Efficacy will be assessed by
      evaluating the effect of LUM001 on the biochemical markers and pruritus associated with
      Alagille Syndrome.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Male or female, 12 months to 18 years of age.

          2. Competent to provide informed consent and assent (per institutional review
             board/Ethics Committee [IRB/EC]), as appropriate.

          3. Completed participation in the LUM001-301 protocol.

          4. Females of childbearing potential must have a negative urine pregnancy test [beta
             human chorionic gonadotropin (beta-hCG)] at the Baseline Visit.

          5. Sexually active females must be prepared to use an effective method of contraception
             during the trial.

             Effective methods of contraception are considered to be:

               1. Hormonal (for example, contraceptive pill, patch, intramuscular implant or
                  injection); or

               2. Barrier method, for example, (a) condom with spermicide, or (b) diaphragm, with
                  spermicide; or

               3. Intrauterine device (IUD).

          6. Participants above the age of assent and caregivers and children must be able to read
             and understand English or Spanish.

          7. Caregivers (and age appropriate participants) must have access to phone for scheduled
             calls from study site.

          8. Caregivers (and age appropriate participants) must be willing and able to complete a
             daily electronic diary (ItchRO) during the first consecutive 12 weeks of the study and
             then for 4 consecutive weeks following the Week 24 and Week 44 visits.

          9. Caregivers (and age appropriate participants) must digitally accept the licensing
             agreement in the ItchRO electronic diary software at the outset of the study.

         10. Eligible participants must be able to adhere to local Ethics Committee or
             Institutional Review Board (IRB) blood volume limits for laboratory testing.

         11. The participant has completed the protocol either through Week 144, or the End of
             Trial visit, or has received permission from the sponsor and the Premier Medical
             monitor to re-enter the study in the long-term, optional follow-up treatment period 2.

         12. Females of child-bearing potential must have a negative urine or serum pregnancy test
             (beta-HCG]) at the time of entry into the long-term optional follow-up treatment
             period 2.

         13. Male and female participants of child-bearing potential who are sexually active, or
             are not currently sexually active, but become sexually active during the study or for
             30 days following the last dose of study drug, must agree to use acceptable
             contraception during the study.

         14. Informed consent and assent (per IRB/EC) as appropriate.

         15. Caregivers (and age appropriate participants) must have access to phone for scheduled
             calls from study site.

         16. Caregivers (and age appropriate participants) must be willing to follow the rules of
             eDiary completion.

        Exclusion Criteria:

          1. Experienced an adverse event or serious adverse event (SAE) related to the study drug
             during the LUM001-301 protocol that led to the discontinuation of the participant from
             the core study.

          2. Any conditions or abnormalities (including laboratory abnormalities) which in the
             opinion of the Investigator, Medical Monitor or ChiLDReN Protocol Chair, may
             compromise the safety of the participant, or interfere with the participant
             participating in or completing the study.

          3. History or known presence of gallstones or kidney stones.

          4. History of non-adherence during the participant's participation in the LUM001-301
             protocol. Non-adherence is defined by dosing compliance (dosing compliance is
             calculated by [the total number of doses that were actually taken by the participant]
             divided by [the total number of doses that should have been taken by the participant]
             multiplied by 100) of less than 80% in the LUM001-301 protocol.

          5. Unlikely to comply with the study protocol, or unsuitable for any other reason, as
             judged by the investigator.

          6. All above exclusion criteria will apply upon re-entry into the long-term, optional
             follow-up treatment period 2.